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Abstract
Background: The ethical, methodological, and technical aspects of pediatric research, often results in complications
and delays in implementation. Our objective was to identify factors associated with the implementation duration of
hospital-based pediatric studies.
Methods: All hospital-based pediatric studies sponsored by AP-HP between 2002 and 2008 were retrospectively
identified. Association of the funding mechanism and methodological factors with the implementation duration
was assessed using a multivariable mixed linear model. Pharmaceutical factors were explored as part of a subgroup
analysis restricted to the studies involving drug therapy. Given that we took an exploratory approach, factors
associated with implementation duration with p < 0.10 were kept in the final models.
Results: A total of 139 studies were evaluated. The median implementation duration was 17.1 months (range:
0.9-55.3 months), and tended to increase over time (from 14.9 [25th percentile-75th percentile: 11.5-19.9] months in
2002 to 23.7 [15.2-31.0] months in 2008, p = 0.01). External (coefficient [95 % confidence interval]: -7.7 [-11.9;-3.5]
months, p < 0.001) and internal funding (-5.3 95 % CI [-9.8;-0.8], p = 0.02) compared to governmental funding and
number of centers (-0.1 95 % CI[-0.2;0.02] months for 1 center increase, p = 0.07) were associated with reduced
duration, whereas interventional study (either involving drug therapy (6.0 95 % CI[0.7;11.3] months, p = 0.03 or not
(3.5 95 % CI[-0.3;7.3] months, p = 0.06) was associated with increased duration compared to observational study.
Regarding the 35 studies involving drug therapy, external funding decreased duration (-6.7 95 % CI[-13.2;-0.2]
months, p = 0.05), whereas studies involving solely a pediatric population (7.8 95 % CI[1.1;14.5] months, p = 0.01)
(compared to mixed adult-pediatric population), a placebo-controlled design (6.6 95 % CI[0.9;12.3] months, p = 0.01),
and inappropriate drug formulation for at least one drug used in the study (6.9 95 % CI[-0.2;14.0] months, p = 0.06)
were associated with increased duration.
Conclusion: Implementation of hospital-based pediatric studies primarily faced delays when they were
interventional and, in particular, when they involved drug therapy. Regarding the latter, difficulties that resulted in
delayed studies arose with respect to the supply of drugs and placebo in age-appropriate dosages and route of
administration. Therefore, difficulties related to the use of pharmaceuticals need to be anticipated earlier in order to
avoid implementation delays.
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Background
Pediatric research faces specific ethical, methodological,
and technical obstacles [1–4]. Moreover, the lack of fi-
nancial rewards for the pharmaceutical industry is an
additional obstacle for pediatric clinical trials that
involve drug therapy [5, 6]. Those obstacles are well rec-
ognized and result in a lack of pediatric clinical studies
[7, 8]. To address the paucity of pediatric research and
to encourage investment by pharmaceutical companies,
the United States and Europe enacted new legislations
around efficacy and safety of drug trials in children [9–16].
Those legislations have led to significant improvements in
patient safety, trial validity, data reliability, and has ad-
dressed the availability of drugs with age-appropriate infor-
mation [17, 18]. However, the overall impact on the
number of clinical trials performed remains modest [8, 19],
and only a moderate correlation exists between the clinical
trial activity and the pediatric burden of disease [20]. Fur-
thermore, it has been shown that drugs frequently used in
pediatric patients were underrepresented among drugs
qualifying for pediatric exclusivity [17, 21–23]. Therefore,
in addition to industry-driven research, hospital-based in-
vestigation of pediatric drug therapy is needed [23, 24].
However, previous studies identified the heavy regula-
tory burden [5, 25–28], the pharmaceutical issues and
difficulties in establishing contracts with pharmaceutical
companies [25, 26, 29–32], the inadequate training of in-
vestigators, difficulty functioning as both clinician and
investigator [5, 25, 27, 33–37], as well as suboptimal
communication across disciplines involved [25], as the
main obstacles in conducting academic pediatric studies.
Further obstacles relate to the complexity of the 2001
European directive and variability in its interpretation
across European Union countries which have resulted in
further delays in conducting trials, and has contributed
to the loss of European competitiveness in academic re-
search over the past decade [24, 38]. Delays affect the
competitiveness and attractiveness of European clinical
research, and may also be deleterious for the patients,
which dissuades some medical doctors from participa-
tion in clinical trials [5, 25, 26, 33]. In July, 2012, the
European Commission finalized a proposal for a Clinical
Trial Regulation, which would replace the 2001 European
directive [39]. The regulation aims at facilitating the im-
plementation of clinical trials and reducing the regulatory
burden via a risk-proportionate approach. Thus, it should
result in the reduction of both duration and cost for trial
implementation. In the context of the ongoing discussion
on the European Clinical Trial Regulation, it is of interest
to quantify the factors involved in delayed trial implemen-
tation. It should allow ultimately for an improved under-
standing of the obstacles faced by research stakeholders
(e.g. investigators, pharmacists, methodologists, and spon-
sor representatives), the facilitation of collaboration across
involved disciplines, and the development of preventive
strategies.
The objective of this study was to identify factors asso-
ciated with the implementation duration of hospital-
based pediatric studies.
Methods
Ethics statement
This study did not involve any patients and, therefore,
required neither written consent nor information sheet.
The Institutional Review Board of the Paris North
Hospitals, Paris 7 University, Paris Public Hospital Net-
work (AP-HP), approved the study protocol (N° 12-049).
Selection of studies
All hospital-based pediatric studies sponsored by the As-
sistance publique – Hôpitaux de Paris (AP-HP) between
January 1, 2002 and December 31, 2008 were selected.
AP-HP is the public hospital system of the city of Paris
and its suburbs. An additional file describes the French
hospital-based Biomedical Research System, and the AP-
HP division in more detail (Additional file 1). Studies
were retrieved from the AP-HP sponsor’s database
(recording all AP-HP-sponsored studies) and from the
AP-HP central pharmacy’s database (recording all stud-
ies AP-HP-sponsored and involving drug therapy). The
AP-HP central pharmacy is in charge of the pharmaceut-
ical process for AP-HP-sponsored biomedical research.
Data collection
This study is part of a larger project aimed at under-
standing the issues faced by all stakeholders during a
study’s implementation. Data were collected between
2009 and 2010. We first conducted a qualitative study
on the perceptions and experiences of healthcare profes-
sionals involved in pediatric hospital-based research
(principal investigators, pharmacists, sponsor representa-
tives, French drug agency representatives) [25]. The
current study was based on the knowledge and under-
standing gained from this qualitative analysis.
Data were collected using a web-based Case Report
Form system specifically developed for the study (Janus,
PHP) from the AP-HP sponsor’s database, the AP-HP
central pharmacy’s database, and the studies’ protocols.
Missing data were sought in the ClinicalTrials.gov regis-
try [40], and publications related to the studies. Ultim-
ately, the involved Clinical Trial Units and investigators
were asked to provide the remainder of missing data.
Collected data included information on funding and
study methodology. Pharmaceutical information was
collected for the studies involving drug therapy. Data re-
lated to funding included the date of grant approval and
the funding mechanism (governmental funding, AP-HP
internal funding, or external funding). External funding
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corresponds to funding from pharmaceutical companies,
associations, or foundations. Data related to the method-
ology were: type of the coordinating center (pediatric
hospital, general hospital), number of centers, whether
the study was international or national, study type (inter-
ventional involving drug therapy, interventional without
drug therapy, observational), characteristics of the dis-
ease (whether the disease was rare and/or chronic),
study population (pediatric population only, or mixed
population, i.e., including children and adults), number
of patients to include, and participation duration of the
subjects. Data related to the pharmaceutical aspects
were: randomization, blinded patient, blinded investiga-
tor, duration of treatment, control group (standard treat-
ment, placebo, no control group), whether the drug
therapy was already approved in a pediatric population,
route of administration (enteral, parenteral), and
whether the formulation of the available drug therapy
was in an age-appropriate dosage and route of administra-
tion (appropriate, intermediate, inappropriate). The formu-
lation was defined as intermediate when only capsules were
available for the study, though children under six years,
who were unable to swallow capsules, were included. In
this case, the capsules must be opened to collect the pow-
der which is then incorporated into an aliment or a fluid to
be administrated (except for delayed-release and protective-
coated capsules). The formulation was also defined as inter-
mediate when an injectable form was utilized for enteral
administration. The formulation was defined as inappropri-
ate when only tablets were available for the study, even
though children under 6 years were included. In this situ-
ation, the tablets must be crushed to get a powder, which
then requires an additional pharmaceutical medium to en-
sure that the pharmacological properties and the pharma-
cokinetics of the drug therapy are not altered.
Statistical analysis
Results are expressed as numbers and percentages for
categorical variables and as a mean (standard deviation)
or median [25th percentile;75th percentile] for continu-
ous variables, according to their distribution.
The implementation duration was defined as the time be-
tween the date of grant and the inclusion of the first patient
(i.e. date of first informed consent). Probability over time to
include the first patient was depicted using the inverse
Kaplan-Meier curve. Differences in distribution of imple-
mentation duration according to the funding mechanism
and the methodological factors were assessed using
Pearson’s (or Spearman’s, as appropriate) correlation coeffi-
cient for quantitative variables and t-test (or Wilcoxon test,
as appropriate) for categorical variables. For comparison of
the mean value of the implementation duration across
more than two groups, one-way ANOVA was performed.
Independent prognostic factors of implementation duration
were assessed using a multivariable mixed linear model,
with the random effect of the year of grant [41]. A random
effect was included to adjust for potential residual cluster-
ing of data within the year of the grant. Pharmaceutical fac-
tors were explored as part of a subgroup analysis restricted
to the studies involving drug therapy. For all multivariable
regression models, p < 0.20 was used for the variable entry
criteria. Then, a stepwise selection procedure was applied.
Given that the statistical analyses were essentially explora-
tory, factors associated with the considered outcome with
p < 0.10 were kept in the final model. Variables dropped
at earlier stages were re-evaluated for inclusion in the final
model. Normality of residuals and absence of heterosce-
dasticity were checked.
All tests were two-sided. Statistical analysis was per-
formed using the R package Version 2.10 [42] and SAS
9.2 software (SAS Institute, Cary, NC, USA).
Results
Description of the studies
We identified 145 pediatric studies sponsored by the
AP-HP between 2002 and 2008. Six were excluded since
they stopped before the first inclusion (Table 1). Among
them, 2 were observational studies (33 %), 3 were inter-
ventional studies without drug therapy (50 %), and 1 was
an interventional study involving drug therapy (17 %). A
total of 139 studies were analyzed. Seventy-two (52 %)
were observational studies, 32 (23 %) were interventional
without drug therapy, and 35 (25 %) were interventional
involving drug therapy (Table 1).
The studies mainly focused on rare and chronic dis-
eases. There was no particular trend regarding the num-
ber of studies granted per year. The main source of
funding in observational studies and in interventional
studies without drug therapy was governmental (n = 39/
72, 54 % and n = 20/32, 63 % respectively), whereas
studies involving drug therapy more often involved ex-
ternal funding (n = 14/35, 40 %). There were more
monocentric studies among studies involving drug ther-
apy (p = 0.01), and studies involving drug therapy almost
exclusively included a pediatric population (p = 0.003).
Exploration of factors associated with study
implementation duration
Figure 1 shows the probability over time to include the
first patient (the confidence interval of the probability
appears as a gray cloud). The median implementation
duration was 17.1 months (95 % CI [15.6;19.9] months),
ranging from 0.9 to 55.3 months. The univariate analysis
of factors determining the implementation duration is
presented in Table 2. The funding mechanism, type of
study, and rare disease were associated with the imple-
mentation duration. The implementation duration
tended to increase over time (p = 0.01).
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The multivariable mixed linear model analysis showed
that government funding and interventional studies,
both involving or without drug therapy, were signifi-
cantly associated with delayed implementation, and an
increasingly number of centers tended to be associated
(Table 3).
Exploration of factors associated with implementation
duration of studies involving drug therapy
The pharmaceuticals characteristics of the 35 studies in-
volving drug therapy are shown in Table 4. Studies were
mainly randomized (n = 26, 74 %), 16 (46 %) involved
blinded investigators, 17 (49 %) blinded patients, 13 (37 %)
were placebo controlled, and 9 (26 %) involved a drug ther-
apy with an intermediate or inappropriate formulation with
respect to the age of the participants (n = 3, 9 % and n = 6,
17 % respectively).
The univariate analysis of factors determining the im-
plementation duration of studies involving drug therapy
is presented in Table 2. The funding mechanism, study
population, randomization, blinded patient and/or inves-
tigator, placebo-controlled study status, and drug formu-
lation were associated with implementation duration.
The multivariable mixed linear model analysis showed
that an exclusively pediatric population, placebo-controlled
study, and inappropriate drug formulation were signifi-
cantly associated with delayed implementation for the stud-
ies involving drug therapy (Table 3). Government funding
tended to be associated with delayed implementation.
Discussion
Main results
Our findings show that implementation duration in-
creased over time, with large fluctuations (ranging from
Table 1 Characteristics of the hospital-based pediatric studies sponsored by the Assistance Publique-Hôpitaux de Paris between
2002 and 2008
Characteristics Observational
studies (n = 72)
Interventional studies without
drug therapy (n = 32)
Interventional studies involving
drug therapy (n = 35)
p-value Excluded studies (n = 6)
NA
Funding mechanism 0.07 5
Government 39 (54) 20 (63) 12 (34) 1 (100)
External 20 (28) 4 (13) 14 (40) 0 (0)
Internal 13 (18) 8 (25) 9 (26) 0 (0)
Year of grant - 0
2002 17 (24) 1 (3) 3 (9) 1 (17)
2003 5 (7) 2 (6) 3 (9) 4 (67)
2004 9 (13) 2 (6) 5 (14) 1 (17)
2005 15 (21) 1 (3) 7 (20) 0
2006 6 (8) 5 (16) 6 (17) 0
2007 12 (17) 12 (38) 9 (26) 0
2008 8 (11) 9 (28) 2 (6) 0
Coordinator center 0.31 0
Pediatric hospital 28 (39) 15 (47) 19 (54) 6 (100)
General hospital 44 (61) 17 (53) 16 (46) 0 (0)
Number of centers 6 [2;16] 5 [2;16] 3 [1;15] 0.78 1 [1;1] 1
Monocentric study 12 (17) 5 (15.6) 14 (40) 0.01 4 (80) 1
International study 1 (1) 0 (0) 4 (11) 0.006 0 (0) 0
Rare disease 50 (69) 20 (63) 27 (77) 0.43 4 (67) 0
Chronic disease 60 (83) 22 (69) 26 (74) 0.22 4 (67) 0
Study population 0.003 0
Pediatric 30 (42) 19 (59) 27 (77) 6 (100)
Mixed (children and adults) 42 (58) 13 (41) 8 (23) 0 (0)
Number of patients to include 150 [82;388] 128 [66;240] 60 [36;100] 0.12 20 [20;25] 3
Length of participation, months 0.2 [0.03;12] 4 [0.2;17] 8 [0.5;24] 0.61 0.1 [0.03;2] 2
Referenced in ClinicalTrials.gov 21 (29) 32 (100) 24 (69) <0.001 1 (17) 0
Values shown are median [25th percentile; 75th percentile] and number (percentage)
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1 to 55 months) depending on the funding mechanism,
number of centers involved, and type of study. There
was no particular trend regarding the number of studies
granted per year.
Government funding was associated with delayed
implementation as compared to external (-7.7 95 %
CI[-11.9;-3.5] months, p < 0.001) and internal funding
(-5.3 95 % CI[-9.8;-0.8] months, p = 0.02). One main ex-
planation was that the time needed to mobilize resources
is longer for government funding than for the other types
of funding. Indeed, while there is a specific process that
must be undertaken in order to mobilize resources from
the government, money dedicated to internal funding is
held by the AP-HP sponsor and can be immediately mobi-
lized. Similarly, external funding from pharmaceutical
companies, associations, and foundations can be rapidly
mobilized. Furthermore, internal funding provides a lower
overall amount of funding (≤100,000 euros) than does
government funding. It is, therefore, dedicated in principle
to smaller studies, and the regulatory process is less com-
plicated than for government funding. This may also ex-
plain why studies with internal funding started earlier
than studies with government funding. Finally, the bene-
fits of sharing expertise, resources and competences in the
context of external funding might reduce implementation
duration as compared to studies with government funding
[12, 43, 44].
Interventional studies started later than observational
studies, which is consistent with the heavier regulatory
requirements to meet before the first inclusion in such
studies. Interventional studies involving drug therapy
were more delayed (6.0 ± 2.7 months, p = 0.03) than
interventional studies without drug therapy (3.5 ± 1.9
months, p = 0.06). It would be of interest to future stud-
ies to compare the complexity and issues faced by the
different stakeholders when implementing interventional
studies with and without drug therapy.
Multi-center studies tended to include the first patient
quicker than single center studies. Indeed, increasing the
number of centers increases recruitment capacity, and
thus the probability to include the first patient much
earlier. However, involving many sites also results in a
complex study set-up. Therefore, the number of patients
and centers to involve should be considered carefully
and in a well-balanced manner.
With regard to the subgroup of studies involving drug
therapy, our findings again showed that government fund-
ing was associated with delayed implementation as com-
pared to external funding (-6.7 ± 3.2 months, p = 0.05).
Among the 35 studies involving drug therapy, 40 % had
an external funding source. Given that external funding in
studies involving drug therapy typically comes from
pharmaceutical companies, this finding might reflect the
benefit of public-private partnerships. The benefit of
public-private partnerships seems even more apparent
since there is no significant difference in the implementa-
tion duration between studies with government funding
and studies with internal funding (-2.9 ± 3.4 months,
p = 0.41) in this subgroup of studies.
Finally, pharmaceutical factors determining the imple-
mentation duration were identified. Age-inappropriate drug
formulation and placebo-controlled studies significantly
Fig. 1 Probability over time to include the first patient
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Table 2 Bivariate analyses of factors associated with the duration of the study implementation: a- all included studies (n = 139),
b- restricted to studies involving drug therapy (n = 35)
a-All studies (n = 139) b-Studies involving drug therapy (n = 35)
Characteristics Implementation duration in
months, or correlation coefficient
p-value Implementation duration in
months, or correlation coefficient
p-value
Grant characteristics
Funding mechanism 0.002 0.007
Government 22.6 (11.3) 25.2 [21.2;31.7]
External 15.3 (9.5) 13.7 [11.9;17.3]
Internal 18.9 (8.9) 18.0 [15.9;31.9]
Year of grant 0.01 0.13
2002 14.9 [11.5;19.9] 17.8 [16.0;32.9]
2003 19.1 [13.1;30.5] 22.8 [14.8;28.0]
2004 17.4 [12.5;22.4] 15.9 [15.2;17.4]
2005 12.3 [10.8;16.6] 15.9 [12.9;17.1]
2006 20.8 [14.5;27.3] 22.1 [14.5;27.0]
2007 20.9 [15.5;30.0] 21.7 [14.0;29.4]
2008 23.7 [15.2;31.0] 36.5 [34.2;38.7]
Methodological characteristics
Coordinator center 0.85 0.46
General hospital 19.7 (10.9) 17.2 [13.7;24.4]
Pediatric hospital 20.0 (10.7) 19.4 [15.1;29.6]
Number of centers ρ = -0.09 0.32 ρ = 0.09 0.62
Type of study 0.03 -
Interventional involving drug therapy 17.8 [13.9;28.3] -
Interventional without drug therapy 20.4 [14.8;30.1] -
Observational 15.5 [11.0;21.3] -
International study 0.81 0.77
Yes 21.7 [13.8;22.8] 22.2 [19.7;25.1]
No 16.5 [12.7;24.3] 17.2 [14.1;30.8]
Rare disease 0.007 0.30
Yes 21.1 (12.0) 19.4 [13.9;30.4]
No 16.8 (6.4) 16.6 [15.2;18.1]
Chronic disease 0.65 0.31
Yes 19.6 (10.3) 19.7 [14.1;29.4]
No 20.7 (12.3) 15.9 [13.3;17.4]
Study population 0.34 0.05
Pediatric population 20.7 (10.7) 19.4 [15.9;29.4]
Mixed population 18.9 (10.9) 13.9 [10.6;17.2]
Length of participation ρ = 0.08 0.36 ρ = 0.12 0.49
Pharmaceutical characteristics
Inclusion of children under 6 years old - 0.24
Yes - 15.9 [13.4;18.7]
No - 18.7 [14.2;29.9]
Randomized study - 0.04
Yes - 20.8 [15.4;30.8]
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increased the implementation duration (respectively 6.9 ±
3.5 months, p = 0.06 and 6.6 ± 2.8 months, p = 0.01). Look-
ing into the order history of these studies and/or meeting
the stakeholders, we discovered that these studies had
faced such issues as unexpected placebo, or problems
with the supply of an age-appropriate drug formula-
tion. In these situations, drug formulation develop-
ment was instead carried out by hospital pharmacies
or subcontractors, which resulted in major delays and
supplementary costs.
Strengths and weaknesses of the study (internal validity)
This study is the first to quantify the implementation
duration of hospital-based pediatric clinical studies and
to identify factors independently related to this duration.
A limitation of the study is that the data were collected
in 2009, which prevented us from describing more re-
cent data. However, the issues highlighted by our study
are not specific to this time period and are still relevant
today. Although it is a retrospective study, there were no
missing data and the sources of data were reliable. It
would have been of interest to analyze the association
between the risk level associated to the studies and their
implementation duration; however, this data was not
available. Nevertheless, the type of study closely reflects
this information since the interventional pediatric stud-
ies are usually classified as high risk and the observa-
tional studies as low risk. Indeed, the regulations are
much more stringent for pediatric populations compared
to adult populations [25].
Strengths and weaknesses of the study compared to
other studies (external validity)
We focused on AP-HP-sponsored studies, and therefore
on a single geographic region (the Paris conurbation),
which may limit the external validity of our findings.
However, the AP-HP is the leading academic sponsor in
France, and the leading research center in Europe [45].
Moreover, the issues highlighted by our study are not
specific to the AP-HP institution.
Academic research faces several obstacles for the imple-
mentation of their studies [5, 33], which result in imple-
mentation delays that have been quantified in our study.
A major issue in the implementation of studies is the
regulatory burden. It is widely described in the literature
[5, 46, 47] and highlighted in a qualitative study previ-
ously conducted by our group [25]. The present study
shows that while there was no particular trend regarding
the number of studies granted per year, the implementa-
tion duration increased over time. The increasing imple-
mentation duration over time might be related to an
increasing regulatory burden. Osuntokun described this
increasing regulatory burden over time, and discussed
the difficulty for academic structures to apply the
pediatrics regulations [5]. Indeed, these regulations are
specifically targeted at pharmaceutical companies, and
Table 2 Bivariate analyses of factors associated with the duration of the study implementation: a- all included studies (n = 139),
b- restricted to studies involving drug therapy (n = 35) (Continued)
No - 14.3 [11.9;17.4]
Duration of treatment, days - - ρ = 0.04 0.81
Blinded investigator and/or blinded patient - 0.06
Yes - 23.0 [15.9;31.3]
No - 16.4 [12.3;21.1]
Placebo-controlled study - 0.01
Yes - 29.4 [17.4;31.9]
No - 16.4 [12.3;19.9]
At least a drug of the study not
approved in pediatric population
- 0.33
Yes - 17.4 [14.2;27.8]
No - 22.9 [16.3;28.6]
Age-appropriate formulation - 0.05
Appropriate - 16.7 [13.6;25.3]
Intermediate at least for one drug of the study - 17.4 [17.1;18.7]
Inappropriate at least for one drug of the study - 30.7 [24.6;32.8]
Route of administration - 0.37
Enterally at least for one drug of the study - 20.0 [14.8;30.4]
Parenterally - 17.6 [13.5;21.9]
Values of the duration of the study implementation are reported as mean (Standard Deviation) or median [25th percentile;75th percentile]
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slow down academic research [24, 38]. The upcoming
European Clinical Trial Regulation should be a major
determinant regarding this issue, particularly via the
risk-proportionate approach.
Studies involving drug therapy faced supplementary de-
lays of implementation. Indeed, the complexity introduced
by the pharmaceutical issues in the implementation of
these studies should not be neglected [5, 37, 48]. However,
this complexity is often unanticipated and impacts both,
the investigators and pharmacists [25]. Indeed, due to the
underestimation of pharmaceutical issues, there is often a
delayed involvement of pharmacists in trial implementa-
tion [3, 5, 48]. The logistical issues associated with the
supply of an appropriate drug formulation with regards to
age and route of administration of drug therapy, and/or of
placebo, are frequently underestimated, and can result in
unexpected costs and delays [3, 32, 48–51]. In our study,
one study out of three faced age-related drug formulation
issues, and an age-inappropriate formulation led to signifi-
cantly increased implementation duration. Thus, because
it is not unusual and can increase the implementation
duration, the need of an age-appropriate formulation, as
well as the need for a placebo, should be underscored.
The establishment of a relationship between the pharma-
ceutical companies and the public sector, specifically in
the context of the pediatric research, is not always possible
[49], particularly due to the lack of financial rewards for
the pharmaceutical industry [6, 23]. As a consequence, the
pharmaceutical burden can be increased, and if it is not
anticipated, delays and financial needs might increase in
such a way that it could strongly hamper the course of the
study [37].
Meaning of the study results and implications for
policymakers
This study identifies and characterizes issues that may
be generalizable on a global scale, and would therefore
be of value to the academic pediatric research commu-
nity at large.
Table 3 Analysis of factors associated with the implementation duration using multivariable regression: a- all included studies
(n = 139), b- restricted to studies involving drug therapy (n = 35)
a) All studies, multivariable mixed linear model with a random intercept for year of grant (n = 139)
Variable Coefficient (95 % CI) p-value
Intercept 22.3 (18.5;26.1)
Funding mechanism (ref. = Government) <0.001
External -7.7 (-11.9;-3.5) <0.001
Internal -5.3 (-9.8;-0.8) 0.02
Number of centersa -0.1 (-0.2;0.02) 0.07
Type of study (ref = Observational) 0.003
Interventional involving drug therapy 6.0 (0.7;11.3) 0.03
Interventional without drug therapy 3.5 (-0.3;7.3) 0.06
b) Studies involving drug therapy, using multivariable linear regression (n = 35)
Variable Coefficient (95 % CI) p-value
Intercept 14.9 (6.9;22.9)
Funding mechanism (ref. = Government) 0.08
External -6.7 (-13.2;-0.2) 0.05
Internal -2.9 (-9.8;4.0) 0.41
Study population (ref. = Mixed population) 0.01
Pediatric population 7.8 (1.1;14.5)
Placebo-controlled study 6.6 (0.9;12.3) 0.01
Age-appropriate formulation (ref. = Appropriate) 0.05
Intermediate at least for one drug of the study -3.6 (-13.0;5.8) 0.44
Inappropriate at least for one drug of the study 6.9 (-0.2;14.0) 0.06
aFor an increase of 1 centre
For all multivariable regression models, P < 0.20 was used for the variable entry criteria. Then, a stepwise selection procedure was applied. Because the statistical
analyses were essentially exploratory, factors associated with the considered outcome with P < 0.10 were kept in the final model. Variables dropped at earlier
stages were re-evaluated for inclusion in the final model
Values shown are coefficient, 95 % confidence interval (95 % CI). Individual p-value for each category of the variables are shown (in italics), as well as the global
p-value of the variable (in bold)
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Our findings show that the implementation of inter-
ventional hospital-based studies with government fund-
ing face the most delays.
With regards to interventional studies involving drug
therapy, public-private partnerships appear valuable.
However, pharmaceutical companies are not always re-
sponsive to requests’ partnerships, mainly due to the
lack of return on investment [6, 23]. Academic stake-
holders must then grapple with the complexity of
pediatrics regulations, which are actually targeted at the
pharmaceutical industries. They then face the methodo-
logical, ethical, and technical requirements of pediatric
clinical trials, often with limited financial resources
[5, 38]. The upcoming European Clinical Trial Regu-
lation should be a major determinant regarding this
issue, particularly via the risk-proportionate approach.
Finally, documentation of pharmaceutical feasibility
should be a prerequisite to any grant allocation. The
difficulties in the supply of drugs and placebo in age-
appropriate dosages and appropriate route of administra-
tion formulations should be particularly evaluated. This
measure would ensure adequate funding for the pharma-
ceutical component and would avoid allocating grant
funding to projects that eventually face insurmountable
pharmaceutical obstacles. Raising awareness for stake-
holders around this topic, as well as the development and
validation of pharmaceutical feasibility evaluation tools,
would be a judicious axis for improvement [48].
Conclusion
More pediatric hospital-based studies are needed to ad-
dress the lack of pediatric research. However, the imple-
mentation of such studies faces delays, mainly due to
regulatory and pharmaceutical issues. Regarding clinical
trials, these delays have the potential to decrease with
the upcoming European Clinical Trial Regulation. Al-
though the involvement of the pharmaceutical industry
usually reduces implementation delays, such collabora-
tions are not always possible. In addition, difficulties in
the supply of drugs and placebo in age-appropriate dos-
ages and appropriate route of administration formula-
tions result in delayed studies. Pharmaceutical issues
should, therefore, be anticipated earlier. We encourage
the development of a “Research Pharmacist” specifically
trained in providing early pharmaceutical expertise, and
in developing recommendations consistent with the
methodological constraints of studies.
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